Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:

P491

In patients with active ulcerative colitis, cytapheresis spares corticosteroids, and reduces hospitalisation time: therapeutic outcomes in 181 consecutive patients.

Authors:

O. Nomura*, T. Osada, T. Shibuya, D. Ishikawa, K. Haga, N. Sakamoto, S. Watanabe

Juntendo University, Department of Gastroenterology, Tokyo, Japan

P492

Perioperative complications have long-term effect on quality of life after restorative proctocolectomy

Authors:

Y. Lee1, A. McCombie*1, 2, R. Vanamala1, R. Gearry3, F. Frizelle1, E. McKay1, J. Williman4, T. Eglinton1

1University of Otago, Department of Surgery, Christchurch, New Zealand, 2University of Otago, Department of Medicine, Dunedin, New Zealand, 3University of Otago, Department of Medicine, Christchurch, New Zealand, 4University of Otago, Christchurch, Department of Population Health, Christchurch, New Zealand

P493

Prevalence and risk factors for postoperative septic complications in Crohn’s disease

Authors:

M. Guasch1, 2, A. Clos1, M. Manyosa3, T. Lobatón3, J. R. Gómez2, M. Piñol4, E. Cabré3, J. Troya4, E. Domènech*3

1Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 2Hospital San Jorge, Digestive Surgery, Huesca, Spain, 3Hospital Germans Trias i Pujol. CIBEREHD, Gastroenterology, Badalona, Spain, 4Hospital Universitari Germans Trias i Pujol, Digestive Surgery, Badalona, Spain

P494

Phenotypic analysis revealed features of disease severity in familial versus sporadic cases of inflammatory bowel disease

Authors:

G. Maurizi, M. Giannotta*, V. Almerigogna, S. Biagini, A. Cozzi, G. Macrì, M. Milla

AOU Careggi, Regional Referral Centre of Inflammatory Bowel Disease - Clinical Gastroenterology Division, Florence, Italy

P495

Biosimilar infliximab is effective and safe in inflammatory bowel disease patients naïve to anti-TNF therapy: a tertiary centre experience

Authors:

M. Bortlik*1, 2, M. Kolar1, D. Duricova1, 3, K. Malickova4, V. Hruba1, N. Machkova1, K. Mitrova1, M. Lukas1, M. Lukas1, 4

1Iscare, IBD Clinical and Research Centre, Prague, Czech Republic, 2First Medical Faculty and Central Military Hospital, Charles University, Department of Internal Medicine, Prague, Czech Republic, 3First Medical Faculty, Charles University, Institute of Pharmacology, Prague, Czech Republic, 4First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic

P496

Adalimumab treatment reduces extraintestinal manifestations in patients with moderate-to-severe Crohn’s disease: a pooled analysis

Authors:

E. J. Louis*1, R. Löfberg2, W. Reinisch3, D. Schwartz4, J.-F. Maa5, S. Berg5, B. Huang5, A. W. Wang5, A. M. Robinson5, B. Pappalardo5

1University of Liège and CHU, Liège, Belgium, 2Karolinska Institutet and IBD Unit, Sophiahemmet, Stockholm, Sweden, 3Medical University of Vienna, Vienna, Austria, 4Vanderbilt University Medical Centre, Nashville, United States, 5AbbVie Inc., North Chicago, Illinois, United States

P497

Clinical features and outcomes of tuberculosis in inflammatory bowel disease patients treated with anti-TNF therapy as compared with the general population

Authors:

J. Kim*1, J. P. Im1, J.-J. Yim2, C. K. Lee3, D. I. Park4, C. S. Eun5, S.-A. Jung6, J.E. Shin7, K.-M. Lee8, J. H. Cheon9

1Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, 2Seoul National University College of Medicine, Department of Internal Medicine and Lung Institute, Seoul, South Korea, 3Kyung Hee University School of Medicine, Department of Internal Medicine, Seoul, South Korea, 4Sungkyunkwan University School of Medicine, Department of Internal Medicine, Seoul, South Korea, 5Hanyang University, Department of Internal Medicine, Guri, South Korea, 6Ewha Woman’s University School of Medicine, Department of Internal Medicine, Seoul, South Korea, 7Dankook University College of Medicine, Department of Internal Medicine, Cheonan, South Korea, 8The Catholic University of Korea College of Medicine, Department of Internal Medicine, Seoul, South Korea, 9Yonsei University College of Medicine, Department of Internal Medicine, Seoul, South Korea

P498

Rephrasing the question: a novel simple tool for a more accurate evaluation of inflammatory bowel disease patients’ adherence to therapy

Authors:

T. Engel*1, G. Ben-Haim2, N. Levhar1, R. Eliakim1, S. Ben-Horin1

1Sheba Medical Centre Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Gastroenterology, Ramat Gan, Israel, 2Sheba Medical Centre Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Internal Medicine C, Ramat Gan, Israel

P499

Long-term outcomes of infliximab and predictors of response in 213 patients with ulcerative colitis: a hospital-based cohort study from Korea

Authors:

H. Seo*1, S. H. Park1, K. Chang1, G.-U. Kim1, E. M. Song1, M. Seo1, H.-S. Lee2, S.W. Hwang1, D.-H. Yang1, B. D. Ye1, J.-S. Byeon1, S.-J. Myung1, S.-K. Yang1

1Asan Medical Centre, University of Ulsan College of Medicine, Department of Gastroenterology, Seoul, South Korea, 2Asan Medical Centre, University of Ulsan College of Medicine, Health Screening and Promotion Centre, Seoul, South Korea

P500

Capsule endoscopy reveals small intestinal mucosal Crohn’s disease healing after treatment with adalimumab: preliminary results of the SIMCHA study

Authors:

E. Seidman*1, U. Kopylov2, C.-Y. Chao1, M. Girardin3, M. Starr4

1Research Institute of the McGill University Hospital, Gastroenterology, Montreal, Canada, 2Sheba Medical Centre, Gastroenterology, Tel Hashomer, Tel Aviv, Israel, 3University Hospital of Geneva, Department of Gastroenterology and Hepatology, Geneva, Switzerland, 4Research Institute of the McGill University Health Centre, Rheumatology, Montreal, Canada

P501

Abdominal obesity in Paediatric Crohn’s disease is associated with adipokine dysregulation

Authors:

D. Thangarajah*1, K. E. Chapell1, S. Mandalia1, G. Frost2, J. M. Fell3

1Imperial College, Section of Academic Neonatal Medicine, London, United Kingdom, 2Imperial College, Nutrition and Dietetic Research Group, Faculty of Medicine, London, United Kingdom, 3Chelsea and Westminster Hospital NHS Foundation Trust, Department of Paediatric Gastroenterology, London, United Kingdom

P502

Persistence of remission amongst patients with inflammatory bowel disease after adalimumab therapy is stopped: economic and clinical implications

Authors:

x. Cortés*1, J. R. MOLÉS2, S. Fernández3, J. Clofent3, M. Moreno4, J. Rodriguez3, J. Primo3

1Hospital de Sagunto, Valencia, Spain, 2HOSPITAL DE SAGUNTO, VALENCIA, Spain, 3HOSPITAL DE SAGUNTO, Valencia, Spain, 4Hospital de sagunto, Valencia, Spain

P503

Tacrolimus vs anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study

Authors:

T. Yamamoto*, T. Shimoyama, S. Umegae, K. Matsumoto

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P504

Stability observations in tacrolimus suppositories

Authors:

M. Lie*1, E. Jansen2, P. Hoeben2, R. Zaal3, D. Hodes2, M. Rosman2, W. Loos2, J. van der Woude1

1Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands, 2TioFarma BV, Oud-Beijerland, Netherlands, 3Erasmus Medical Centre, Hospital Pharmacy, Rotterdam, Netherlands

P505

The effect of using a question prompt list in outpatient clinic consultations in a Dutch inflammatory bowel disease population

Authors:

N. Peek-Kuijt*1, M. de Jong1, N. Srivastava2, R. Veenendaal1, P. Maljaars1, L. van Bodegom-Vos3, A. Linn4, A. van der Meulen-de Jong1

1Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, 2Medical Centre Haaglanden, Department of Gastroenterology and Hepatology, The Hague, Netherlands, 3Leiden University Medical Centre, Department of Medical Decision Making, Leiden, Netherlands, 4University of Amsterdam, Amsterdam School of Communication Research (ASCoR), Amsterdam, Netherlands

P506

Serum infliximab and antibodies to infliximab levels in Crohn’s disease and ulcerative colitis patients on long-term maintenance therapy

Authors:

M. Waterman*1, H. Bar Yoseph1, B. Ungar2, S. Ben - Horin2, Y. Chowers1

1Rambam Health Care Campus, Department of Gastroenterology, Haifa, Israel, 2Sheba Medical Centre, Department of Gastroenterology, Ramat Gan, Israel

P507

Clinical role, optimal timing and frequency of measurement of serum infliximab levels and anti-infliximab antibody titres in patients with inflammatory bowel disease

Authors:

R. Bor*1, K. Farkas1, A. Bálint1, A. Milassin1, M. Rutka1, M. Matuz2, F. Nagy1, A. Fábián1, Z. Szepes1, T. Molnar1

1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Faculty of Pharmacy, Szeged, Hungary

P508

Pregnancy outcomes in patients with inflammatory bowel disease experiencing flare ups during foetal development

Authors:

Y. Yokoyama*1, H. Tanaka2, T. Miyazaki1, T. Sato1, M. Kawai1, Y. Kita1, K. Kamikozuru1, M. Iimuro1, N. Hida1, S. Nakamura1

1Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine, Nishinomiya, Japan, 2Hyogo College of Medicine, Department of Obstetrics and Gynaecology, Nishinomiya, Japan

P509

What is the effect of inflammatory bowel disease on sedation rates at colonoscopy?

Authors:

M. Walshe*, C. Moran, G. Horgan, G. Cullen, H. Mulcahy, G. Doherty

St Vincent’s University Hospital, Department of Gastroenterology and Centre for Colorectal Disease, Dublin, Ireland

P510

Skin anergy and latent tuberculosis in inflammatory bowel disease patients

Authors:

C. Herrera de Guise*, V. Robles, N. Borruel, E. Navarro, F. Casellas

Unitat d’Atenció Crohn-Colitis. Hospital Universitari Vall d’Hebron, Digestive Diseases Research, Barcelona, Spain